Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity
摘要:
The human mitotic kinesin Eg5 represents a novel mitotic spindle target for cancer chemotherapy. We previously identified S-trityl-L-cysteine (STLC) and related analogues as selective potent inhibitors of Eg5. We herein report on the development of a series of 4,4,4-triphenylbutan-1-amine inhibitors derived from the STLC scaffold. This new generation systematically improves on potency: the most potent C-trityl analogues exhibit K-i(aPP) <= 10 nM and GI(50) approximate to 50 nM, comparable to results from the phase II clinical benchmark ispinesib. Crystallographic studies reveal that they adopt the same overall binding configuration as S-trityl analogues at an allosteric site formed by loop L5 of Eg5. Evaluation of their druglike properties reveals favorable profiles for future development and, in the clinical candidate ispinesib, moderate hERG and CYP inhibition. One triphenylbutanamine analogue and ispinesib possess very good bioavailability (51% and 45%, respectively), with the former showing in vivo antitumor growth activity in nude mice xenograft studies.
POLY(P-XYLYLENE)-BASED POLYMER HAVING LOW DIELECTRIC CONSTANT AND LOW-LOSS PROPERTY AND INSULATING MATERIAL, PRINTED CIRCUIT BOARD AND FUNCTIONAL ELEMENT USING THE SAME
申请人:CHO Jae-Choon
公开号:US20100048858A1
公开(公告)日:2010-02-25
The present invention relates to a poly(p-xylylene)-based polymer having a low dielectric constant suitable for low loss dielectrics (LLD), and an insulating material, a printed circuit board and a functional element using the same. More particularly, the poly(p-xylylene)-based polymer includes at least one repeat unit expressed by the following formula (1):
wherein, at least one of R1, R2, R7 and R8 is independently substituted or unsubstituted C6-C20 aryl;
the rest of R1 to R8 are each and independently H, substituted or unsubstituted linear C1-C3 alkyl, or substituted or unsubstituted branched C1-C3 alkyl; and
n is an integer of 400 to 900.
Die vorliegende Erfindung betrifft hydrophobe Polymeroberflächen, insbesondere superhydrophobe Polymeroberflächen, enthaltend wenigstens ein Homo- oder Copolymer, welches wenigstens eine Seitenkette mit wenigstens einer fluorsubstituierten Arylgruppe aufweist. Des weiteren betrifft die vorliegende Erfindung ein Verfahren zur Herstellung derartiger Polymeroberflächen, deren Verwendung und Polymere der allgemeinen Formel I:
worin n eine ganze Zahl zwischen 10 und 4.500, bevorzugt zwischen 20 und 2.200 und besonders bevorzugt zwischen 100 und 670 ist.
本发明涉及疏水性聚合物表面,特别是超疏水性聚合物表面,其包含至少一种均聚物或共聚物,该均聚物或共聚物具有至少一条带有至少一个氟取代芳基的侧链。此外,本发明还涉及制备此类聚合物表面的工艺、其用途以及通式 I 的聚合物:
其中 n 是介于 10 和 4500 之间的整数,最好介于 20 和 2200 之间,尤其最好介于 100 和 670 之间。
US8829155B2
申请人:——
公开号:US8829155B2
公开(公告)日:2014-09-09
Triphenylbutanamines: Kinesin Spindle Protein Inhibitors with in Vivo Antitumor Activity
作者:Fang Wang、James A. D. Good、Oliver Rath、Hung Yi Kristal Kaan、Oliver B. Sutcliffe、Simon P. Mackay、Frank Kozielski
DOI:10.1021/jm201195m
日期:2012.2.23
The human mitotic kinesin Eg5 represents a novel mitotic spindle target for cancer chemotherapy. We previously identified S-trityl-L-cysteine (STLC) and related analogues as selective potent inhibitors of Eg5. We herein report on the development of a series of 4,4,4-triphenylbutan-1-amine inhibitors derived from the STLC scaffold. This new generation systematically improves on potency: the most potent C-trityl analogues exhibit K-i(aPP) <= 10 nM and GI(50) approximate to 50 nM, comparable to results from the phase II clinical benchmark ispinesib. Crystallographic studies reveal that they adopt the same overall binding configuration as S-trityl analogues at an allosteric site formed by loop L5 of Eg5. Evaluation of their druglike properties reveals favorable profiles for future development and, in the clinical candidate ispinesib, moderate hERG and CYP inhibition. One triphenylbutanamine analogue and ispinesib possess very good bioavailability (51% and 45%, respectively), with the former showing in vivo antitumor growth activity in nude mice xenograft studies.
Structural modification of S-trityl-L-cysteine. Preparation of some S-(substituted trityl)-L-cysteines and dipeptides of S-trityl-L-cysteine